Tempus AI (NASDAQ:TEM) Shares Up 6.8% – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM)’s share price traded up 6.8% during mid-day trading on Monday . The stock traded as high as $91.45 and last traded at $89.44. 25,048,636 shares changed hands during trading, an increase of 93% from the average session volume of 12,947,475 shares. The stock had previously closed at $83.75.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price target on shares of Tempus AI in a research note on Tuesday, January 14th. Guggenheim assumed coverage on shares of Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 price target on the stock. Loop Capital dropped their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Finally, Piper Sandler reissued a “neutral” rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Tempus AI currently has an average rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Stock Up 6.8 %

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The business’s 50-day moving average is $46.60 and its two-hundred day moving average is $50.37.

Insider Activity at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 476,209 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $49.84, for a total value of $23,734,256.56. Following the completion of the transaction, the chief executive officer now owns 6,502,643 shares in the company, valued at approximately $324,091,727.12. This represents a 6.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David R. Epstein sold 620 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the transaction, the director now owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,401,779 shares of company stock valued at $115,707,361 in the last quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TEM. Kovitz Investment Group Partners LLC acquired a new stake in shares of Tempus AI in the 3rd quarter worth approximately $1,367,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Tempus AI in the 4th quarter worth approximately $1,091,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after acquiring an additional 1,145,698 shares during the period. Captrust Financial Advisors acquired a new stake in shares of Tempus AI in the 3rd quarter worth approximately $2,726,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Tempus AI in the 4th quarter worth approximately $178,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.